Novo strikes RNA drug deal with startup Replicate
The agreement provides research funding for Replicate and up to $550M in payments to develop medicines for diseases including obesity and diabetes.
Previous Post
Digital Health Coffee Time Briefing ☕
Next Post
Medicare Advantage plans frequently deny post-acute care for nursing homes, survey finds
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago